Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis

Dhruv Nayyar; Kavitha Muthiah; Gayathri Kumarasinghe; Ravin Hettiarachchi; David Celermajer; Eugene Kotlyar; Anne Keogh

doi:10.1086/675996

Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis

Pulm Circ. 2014 Jun;4(2):342-5. doi: 10.1086/675996.

Authors

Dhruv Nayyar¹, Kavitha Muthiah², Gayathri Kumarasinghe², Ravin Hettiarachchi¹, David Celermajer², Eugene Kotlyar², Anne Keogh²

Affiliations

¹ St. Vincent's Hospital, Sydney, Australia ; University of New South Wales, Kensington, Australia.
² St. Vincent's Hospital, Sydney, Australia.

PMID: 25006453
PMCID: PMC4070788
DOI: 10.1086/675996

Abstract

Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet-derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.

Publication types

Case Reports